Share This

Related Topics News - Drugs

     
 < Previous page   Detail   |   Print    Next page > 
     
《大行》華泰證券降國藥控股目標價至22.54元 維持「買入」評級
2025-04-02T  
《大行》美銀:微創醫療海外業務潛力強勁 目標價升至9.4元
2025-04-02T  
《大行》美銀重申上海醫藥「買入」評級 目標價降至13.6元
2025-04-01T  
《業績》三愛健康集團全年純利489.2萬人幣跌73.7% 核數師發表保留意見
2025-04-01T  
國家藥監局:加快醫用機械人及AI醫療器械等領域標準制修訂工作
2025-04-01T  
《大行》匯豐研究降國藥控股目標價至18元 維持「持有」評級
2025-03-31T  
《業績》微創醫療全年虧損收窄至2.14億美元
2025-03-30T  
《業績》四環醫藥去年虧損擴大至2.17億人幣 不派息
2025-03-28T  
《業績》上海醫藥全年純利45.53億人民幣增21% 每10股派2.9元人民幣
2025-03-28T  
《大行》瑞銀升威高股份目標價至7.4元 評級「買入」
2025-03-27T  
 < Previous page    Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.